CORDIS
EU research results

CORDIS

English EN

A Humanized Monoclonal Anti-Claudin1 Antibody (anti-CLDN1 mAb) for Treatment of Hepatocellular Carcinoma (HCC)

Project information

Grant agreement ID: 862551

Status

Ongoing project

  • Start date

    1 October 2019

  • End date

    31 March 2021

Funded under:

H2020-EU.1.1.

Hosted by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Project description

English EN

New immunotherapy targets cancerous cells that are immune to current treatment

Liver fibrosis is a scarring process resulting from the liver's response to chronic injury or inflammation. It is caused by viruses, diseases, and alcoholism. Over time, it can lead to cirrhosis, a disruption in the organisation of the functional units of the liver that can eventually impede blood flow to the liver. Fibrosis and cirrhosis are also linked to the development of an aggressive and lethal form of liver cancer. The cancer is characterised by emergence of drug-resistant cell populations in response to the only systemic treatment currently available. Even worse, persistent treatment seems to speed tumour progression. HEPCAN is targeting those drug-resistant cell populations through the development of powerful monoclonal antibodies designed to decimate the resistors.

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Research Organisations

EU Contribution

€ 150 000

Beneficiaries (1)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 150 000

Project information

Grant agreement ID: 862551

Status

Ongoing project

  • Start date

    1 October 2019

  • End date

    31 March 2021

Funded under:

H2020-EU.1.1.

Hosted by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France